Nuveen LLC Makes New $13.05 Million Investment in Establishment Labs Holdings Inc. $ESTA

Key Points

• Nuveen LLC has made a new investment in Establishment Labs Holdings Inc., acquiring 319,919 shares valued at approximately $13.05 million, representing about 1.11% ownership of the company.
• Analysts have mixed views on Establishment Labs, with a consensus rating of "Moderate Buy" and various price targets ranging from $47.00 to $70.00.
• The company's latest quarterly earnings report indicated a revenue increase of 16.1% year-over-year, though it missed EPS expectations with a loss of ($0.57) per share.

Nuveen LLC bought a new position in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 319,919 shares of the company's stock, valued at approximately $13,054,000. Nuveen LLC owned 1.11% of Establishment Labs as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of ESTA. Raymond James Financial Inc. bought a new position in Establishment Labs in the 4th quarter worth $5,494,000. Hood River Capital Management LLC boosted its holdings in Establishment Labs by 236.4% in the 4th quarter. Hood River Capital Management LLC now owns 5,920 shares of the company's stock worth $273,000 after buying an additional 4,160 shares during the period. Adage Capital Partners GP L.L.C. bought a new position in Establishment Labs in the 4th quarter worth $7,261,000. Voya Investment Management LLC boosted its holdings in Establishment Labs by 7,249.5% in the 4th quarter. Voya Investment Management LLC now owns 408,262 shares of the company's stock worth $18,809,000 after buying an additional 402,707 shares during the period. Finally, Nebula Research & Development LLC bought a new position in Establishment Labs in the 4th quarter worth $440,000. Institutional investors own 72.91% of the company's stock.

Establishment Labs Trading Down 6.8%

Shares of NASDAQ:ESTA traded down $2.97 during trading on Monday, reaching $40.66. The company's stock had a trading volume of 353,846 shares, compared to its average volume of 529,593. The company has a current ratio of 2.84, a quick ratio of 1.67 and a debt-to-equity ratio of 9.71. Establishment Labs Holdings Inc. has a 12 month low of $26.56 and a 12 month high of $50.85. The firm's 50 day simple moving average is $40.95 and its two-hundred day simple moving average is $37.42. The stock has a market capitalization of $1.18 billion, a PE ratio of -13.33 and a beta of 0.83.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.03). Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. The business had revenue of $51.30 million during the quarter, compared to the consensus estimate of $50.80 million. During the same period in the previous year, the business posted ($0.62) EPS. The firm's revenue was up 16.1% on a year-over-year basis. Establishment Labs has set its FY 2025 guidance at EPS. On average, research analysts predict that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Analysts Set New Price Targets

ESTA has been the subject of several recent analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $48.00 target price on shares of Establishment Labs in a report on Friday, June 13th. Citigroup raised their price objective on Establishment Labs from $38.00 to $47.00 and gave the company a "neutral" rating in a research report on Wednesday, July 9th. Wall Street Zen lowered Establishment Labs from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Mizuho raised their price objective on Establishment Labs from $58.00 to $70.00 and gave the company an "outperform" rating in a research report on Wednesday, July 16th. Finally, BTIG Research assumed coverage on Establishment Labs in a research report on Friday, May 16th. They set a "buy" rating and a $62.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $56.50.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.